RNS Reach Story
Go to market news section Print

Chronix's ASCO presentation abstract disclosure

Released 07:00 18-May-2017

RNS Number : 4767F
Chronix Biomedical, Inc
18 May 2017

Chronix Biomedical notes abstract disclosure for forthcoming ASCO presentation  

-     Head and neck cancer study finds CNI score to be a stronger predictor of time to recurrence than current method based on lymph node invasion.


San Jose, CA, USA and Göttingen, Germany (18 May 2017) - Chronix Biomedical, Inc., a developer of novel blood-based cancer molecular diagnostics, notes the formal disclosure of the abstract covering its forthcoming presentation of its study in head and neck cancer at the American Society of Clinical Oncology ('ASCO') Annual Meeting on 5 June.


The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer. It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status).


The abstract1 notes that pre-operative CNI scores proved to be a stronger predictor of time to recurrence (p=0.00007) than pN status (p=0.05), with high baseline CNI strongly correlated with time to recurrence (p=0.018). Predicted time to recurrence is an important factor that that can aid the therapeutic decision (i.e. adjuvant treatment) in this condition.


Chronix Biomedical's CMO, Prof. Ekkehard Schütz, commented:

"We look forward to presenting our poster at ASCO and sharing the detailed results of this study with our colleagues in the oncology community at this prestigious meeting."


Chronix is developing a number of tests for the prognosis and diagnosis of cancer and, in particular, the real-time therapeutic monitoring of response to cancer therapy, based on its proprietary copy number instability score. The company intends to conduct validation studies in individual cancers to support regulatory submissions, the most advanced of which, in pancreatic cancer, is already underway. Similar studies in non-small cell lung, colorectal, breast, ovarian and liver cancers are expected to begin later this year.


In the therapeutic monitoring application, Chronix and its collaborators have shown that CNI can accurately determine whether a patient is responding to treatment after just one or two cycles of therapy, potentially 6-8 weeks earlier than is possible using imaging-based methods. Such a test should allow treating physicians to identify the non-responding patients quickly and switch them to alternative treatments sooner, avoiding unnecessary side-effects and potentially achieving better treatment outcomes.


The company has previously presented data from studies of its CNI-based tests in patients receiving radiotherapy, chemotherapy2 and immunotherapy3 and recently published the results of a study in patients receiving immunotherapy in the journal, Clinical Cancer Research4.


About Chronix Biomedical

Chronix Biomedical, Inc. is a US-based molecular diagnostics company developing blood tests for the screening and monitoring of cancer. Chronix's tests use proprietary algorithms to derive a copy number instability (CNI) score from sequencing of circulating cell-free tumour DNA (cfDNA), which can be used in the prognosis, diagnosis and monitoring of therapeutic response to cancer. For more information visit www.chronixbiomedical.com.




1 The abstract (#6055) may be viewed on www.abstracts.asco.org
2 Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers,
   Weiss et al, American Association for Cancer Research 2016 Annual Meeting (
see link).

3 Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2" 

   http://meetinglibrary.asco.org/content/166601-176 Weiss et al.

4 Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy, Weiss et al. 

Clin Cancer Res. 2017 Mar 20. pii: clincanres.0231.2017. doi: 10.1158/1078-0432.CCR-17-0231.



Chronix Biomedical, Inc
Dr Howard Urnovitz, CEO

+1 (408) 960-2307




Shard Capital Partners LLP
(Corporate Adviser and Broker)

Dr Wang Chong

+44 20 7186 9948





This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Chronix's ASCO presentation abstract disclosure - RNS